Main Uses and Benefits of Selexipag

Selexipag is commonly used for the long-term management of Pulmonary Arterial Hypertension (PAH), which is a chronic condition marked by increased physiological stress in the arteries of the lungs. Its primary therapeutic use is to help manage the progression of the disease and is relevant in contexts involving easing the risk of hospitalization due to PAH-related complications, supporting a sense of stability in disease management.

---

The medicine is considered relevant for adult patients who experience symptoms that interfere with daily functioning, such as undue shortness of breath and fatigue during physical activity. It helps address these symptom clusters and offers supportive relief that may assist with maintaining functional stability and contributes to easing the overall symptom load. The conditions where Selexipag is commonly used include idiopathic, heritable, or connective tissue disease-associated PAH.

“This therapy is applied across domains where additional symptomatic support is needed alongside existing oral PAH treatments.”

---

Supporting Treatment Strategies

This medication is often utilized as a component in advanced, multi-drug regimens and is commonly used in combination with other existing oral PAH treatments. It also assists with maintaining treatment continuity, as an intravenous formulation may be used as a bridging therapy when patients are temporarily unable to take the oral tablets, supporting the patient during difficult episodes by easing distress.

Quick Fact: Supportive Management for Functional Limitation

Who can and cannot use Selexipag?

Selexipag eligibility is strictly defined by regulatory authorities and is based on a patient's age, physiological state, and co-existing conditions. The medicine is primarily indicated for adult patients with Pulmonary Arterial Hypertension (PAH), specifically those with WHO Functional Class II–III symptoms.

---

Absolute Prohibitions (Contraindications)

Selexipag is contraindicated and must not be used in the following populations:

• Patients with known hypersensitivity to the active substance or its excipients.
• Patients with a recent history of severe cardiovascular events, including myocardial infarction (within 6 months) or stroke/TIA (within 3 months).
• Patients with severe coronary artery disease or unstable angina.
• Concomitant use with strong inhibitors of the CYP2C8 enzyme, such as gemfibrozil.

---

Populations with Use Restrictions

• Age: Use is not recommended in the pediatric population (under 18 years) as safety and effectiveness have not been established.
• Hepatic Function: Patients with severe hepatic impairment (Child-Pugh Class C) should avoid use. For moderate impairment, dose adjustments are required.
• Pregnancy/Lactation: Use is not recommended during pregnancy. Women of childbearing potential should use effective contraception. The regulatory label advises a decision to discontinue nursing or discontinue the medicine during lactation.

Selexipag is metabolized by the enzyme CYP2 C8 and UGT1 A3. Its active metabolite, ACT-333679 (which is significantly more potent), is metabolized by CYP3 A4 and CYP2 C8. Therefore, drugs that affect these enzymes can alter the concentrations of Selexipag and its active metabolite, potentially leading to increased side effects or reduced efficacy.

---

Key Drug Interactions

Interaction Type	Example Medicines	Clinical Effect / Recommendation
CYP2 C8 Inhibitors	Gemfibrozil, Clopidogrel	Significantly increases ACT-333679 exposure. Selexipag starting dose should be reduced and/or carefully monitored.
CYP3 A4 Inhibitors	Ketoconazole, Erythromycin, Diltiazem	Increases exposure to ACT-333679, requiring caution and potential dose adjustment, especially with strong inhibitors.
CYP2 C8 Inducers	Rifampicin	Significantly decreases ACT-333679 exposure, reducing Selexipag efficacy. Avoid co-administration if possible.
CYP3 A4 Inducers	Carbamazepine, Phenytoin	Decreases active metabolite concentration, potentially lowering therapeutic effect.

---

Other Considerations

Concomitant use with other Prostacyclin Analogues (like epoprostenol or treprostinil) should be avoided due to the potential for additive effects and increased risk of adverse events such as flushing, headache, and hypotension. Patients should always inform their healthcare provider of all prescription, over-the-counter, and herbal supplements they are taking to manage potential interactions safely.

How Selexipag Works

Selective Prostacyclin Receptor Agonism

Selexipag is a selective prostacyclin (IP) receptor agonist. After administration, it is rapidly hydrolyzed to its active metabolite, which binds to and activates the IP receptor, a G-protein coupled receptor, within the pulmonary vasculature. This engagement initiates a critical intracellular signaling sequence.

Intracellular cAMP Cascade Activation

Binding to the IP receptor stimulates the adenylyl cyclase enzyme. This action catalyzes the formation of the secondary messenger cyclic adenosine monophosphate (cAMP), leading to a rise in its intracellular concentration. The elevated cAMP modulates multiple downstream effects within the pulmonary arterial cells.

Vascular Tone and Cellular Proliferation Modulation

The increased cAMP concentration directly mediates the relaxation of pulmonary arterial vascular smooth muscle cells, resulting in vasodilation and a reduction in vascular resistance. Furthermore, this pathway modification inhibits smooth muscle cell proliferation and platelet aggregation, decreasing cell division and preventing platelet activation at the cellular level.

Official Administration Guidelines

Selexipag is intended for long-term use and is available in two official routes of administration: oral film-coated tablets and a sterile powder for intravenous (IV) injection. The IV formulation is used temporarily when a patient is unable to take the oral tablets, supporting treatment continuity.

Dosing and Titration

Treatment begins with a starting dose of 200mu g taken twice daily (BID). The core usage principle is to gradually increase the dose based on individual tolerability. The dose is escalated by increments of 200mu g BID, typically at weekly intervals, until the highest tolerated dose is reached, up to a labeled maximum of 1600mu g BID. The highest dose achieved during this process then becomes the maintenance dose.

Administration Instructions

To help improve tolerability, the oral tablets should be taken with food. The film-coated tablets must be swallowed whole and must not be split, crushed, or chewed. The IV formulation is administered as a continuous infusion over approximately 80 minutes and requires dilution and protection from light during preparation.

Handling Interruptions and Dose Adjustments

If a dose is missed, it should be taken as soon as remembered, unless the next dose is due within the subsequent six hours. If treatment is interrupted for three days or more, the drug must be restarted at a lower dose and then retitrated. For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose is reduced to 200mu g once daily or 100mu g twice daily, and the maximum dose is limited. Use is avoided in patients with severe hepatic impairment.

Research evidence / Overview of studies

Overview of Clinical Evidence

Clinical research has evaluated Selexipag for the long-term management of Pulmonary Arterial Hypertension (PAH). The drug is an oral, selective prostacyclin receptor (IP receptor) agonist.

The large, randomized, placebo-controlled GRIPHON study was the primary phase 3 trial. This trial included patients with PAH across various World Health Organization (WHO) Functional Classes (primarily II and III) and with or without background PAH therapy.

Key findings from the GRIPHON study and its long-term open-label extension (OLE) included the following:

• Risk of Events: The treatment was associated with a lower risk of the composite primary endpoint (a combination of PAH-related complications or death) compared to placebo.
• Long-Term Data: Extended follow-up data has provided the longest duration of observation published to date for an oral PAH therapy, allowing for evaluation of long-term safety and survival.

Pharmacokinetics and Study Administration

Studies reporting on pharmacokinetics have evaluated the administration of Selexipag, noting that the drug is rapidly converted into an active, more potent metabolite. The long half-life of this active metabolite supports its twice-daily dosing regimen.

Research has also examined the potential risks related to drug interactions, specifically with strong CYP2C8 inhibitors, due to the drug's metabolism pathways.

Safety and Tolerability Profile

Research has investigated Adverse Events (AEs). In the studies reviewed, the most frequently reported adverse events were generally consistent with the known effects of prostacyclin pathway therapies, including headache, diarrhea, jaw pain, and nausea. The incidence of adverse events was lower during the long-term maintenance phase of treatment.

Research evaluated the long-term safety profile; no new serious adverse events were reported across the extended follow-up of patients treated with Selexipag. The drug's long-term profile is an ongoing subject of investigation.

Common questions about Selexipag (FAQ)

Q: Is Selexipag a type of blood pressure medication?

A: Selexipag is specifically approved to treat Pulmonary Arterial Hypertension (PAH), which is high blood pressure confined to the arteries of the lungs. Its action of dilating (widening) blood vessels is how it helps reduce pressure in the lungs. Official information indicates that, due to this vasodilatory effect, a potential side effect is a drop in systemic blood pressure, or hypotension.

---

Q: What are the benefits of Selexipag compared to other PAH treatments?

A: Clinical studies indicate its use is associated with a lower risk of disease progression and hospitalization related to PAH complications. It is also supplied as an oral tablet, which can offer a less invasive route of long-term administration compared to some continuously infused prostacyclin-pathway therapies.

---

Q: How quickly should I expect to feel a difference after starting Selexipag?

A: Selexipag treatment starts at a very low dose and must be increased gradually over several weeks. Because the dose is slowly adjusted, a process determined by how well the treatment is tolerated, the full therapeutic effect and symptom improvement are typically gradual.

---

Q: How long do the initial side effects of Selexipag typically last?

A: Side effects such as headache, diarrhea, and jaw pain are very common during the initial dose titration phase (when the dose is being increased). These effects are often transient and can typically be managed. They may lessen or resolve once the long-term maintenance dose is reached.

---

Q: What happens if I forget to take a dose of Selexipag?

A: Official guidelines recommend taking the dose as soon as remembered, unless the next scheduled dose is due within the subsequent six hours. If the medicine is interrupted for three or more consecutive days, restarting treatment often requires a professional to prescribe a lower dose and begin the titration process again.

---

Q: Is it better to take Selexipag with or without food?

A: Official product information recommends taking the oral tablets with food. This instruction is given to help improve the medicine's tolerability, especially during the initial phase of treatment.

---

Q: Can I split or crush Selexipag tablets?

A: No. The film-coated tablets must be swallowed whole and should not be split, crushed, or chewed. This is to ensure proper release and absorption of the medicine as intended by the manufacturer.

---

Q: Is Selexipag typically used alone or with other PAH medications?

A: Selexipag is indicated for the treatment of PAH and may be used as the sole treatment (monotherapy) or in combination with other PAH-specific medications, such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors.

---

Q: What is the maximum dose of Selexipag a person can take?

A: The maximum recommended labeled dose is 1600 mu g taken twice daily. However, the maintenance dose is individually determined by a healthcare provider based on the highest dose tolerated. Patients with moderate liver impairment have a specific lower maximum dose limit.

---

Q: Will I need to take Selexipag forever for PAH?

A: Selexipag is indicated and intended for the long-term use and management of Pulmonary Arterial Hypertension.

---

Q: Does Selexipag have a withdrawal effect if stopped suddenly?

A: Discontinuation of medicines in this class may be associated with a risk of worsening pulmonary hypertension. For this reason, official guidelines require that if the drug is stopped for three or more days, it must be restarted with a new titration from a lower dose.

---

Q: Is Selexipag used for any other conditions besides PAH?

A: According to regulatory indications, Selexipag is specifically approved only for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group I).

---

Q: What is the typical timeframe for increasing the dose of Selexipag?

A: The dose is increased gradually, typically at weekly intervals (every 7 days), until the highest dose that can be tolerated is reached. The goal is to reach this individualized maintenance dose through a slow adjustment process.

---

Q: Do children ever take Selexipag for PAH?

A: Use of Selexipag is not recommended in the pediatric population (patients under 18 years of age). This is because regulatory authorities have not yet established the safety and effectiveness of the drug for treating PAH in children.

---

Q: Can Selexipag affect kidney function?

A: No dosage adjustment is typically required for patients with mild to moderate kidney impairment. However, there is limited clinical experience with patients who have severe kidney impairment or who are on dialysis. Assessment of kidney function is a standard consideration before initiating treatment.

---

Q: What are the signs of an allergic reaction to Selexipag?

A: Selexipag is contraindicated for patients with a known hypersensitivity to the drug or its components. Signs of a serious allergic reaction may include difficulty breathing, or swelling of the face, lips, tongue, or throat.

---

Q: Are there genetic factors that might affect how well Selexipag works?

A: The drug is metabolized (broken down) in the body by specific liver enzymes, notably CYP2C8 and CYP3A4. Genetic variations in these enzymes could potentially affect the concentration of the active medicine in the bloodstream, which is a key reason for caution when co-administering certain enzyme-affecting medications.

---

Q: Does Selexipag require any special monitoring like blood tests?

A: While routine blood monitoring for the drug level itself is not required, the drug label notes the occurrence of anemia (a low red blood cell count) as a common side effect. Due to the potential for anemia, some patients may require monitoring of their hemoglobin levels as determined by their healthcare provider.

---

Q: Can Selexipag make you feel dizzy or lightheaded?

A: Yes, dizziness or lightheadedness may occur. These are common symptoms related to the drug's vasodilatory effects that can cause hypotension (low blood pressure), which is a known side effect.

---

Q: Are there any dietary restrictions I need to follow while on Selexipag?

A: Official product information does not list general food restrictions, but does specify taking the tablets with food to improve tolerability.

Storage and Disposal of Selexipag (UPTRAVI®)

Official instructions for storing Selexipag differ based on the formulation.

---

Oral Tablets

Oral tablets must be stored at controlled room temperature (15 C to 30 C or 59 F to 86 F) and protected from moisture and excess heat. The tablets must be kept in the container they came in, tightly closed. The film-coated tablets must not be split, crushed, or chewed. Bottles of tablets must be used within 3 months of opening.

---

IV Formulation

Unopened IV vials require storage in a refrigerator (2 C to 8 C or 36 F to 46 F) in the original carton to protect from light. Once the solution is prepared, it must be infused within 4 hours.

---

Disposal

All medicines, including Selexipag, must be kept out of the sight and reach of children. Unused or expired tablets should not be thrown away via wastewater or household waste; professional medical waste protocols apply to the IV formulation. Ask a pharmacist or healthcare provider about local disposal programs.